SPY334.19+5.46 1.66%
DIA275.90+4.20 1.55%
IXIC11,117.53+203.96 1.87%

UPDATE: Goldman On Incyte Notes 'we are constructive on the dermatology franchise (topical ruxolitinib in atopic dermatitis and vitiligo) which represents optionality (not included in model), with Ph3 TRuE-AD data for the former in 1H20'

Benzinga · 01/03/2020 15:38